Peptides Tirzepatide 2/5/10mg CAS：2023788-19-2

  ↵

Tirzepatide is an innovative drug for the treatment of **type 2 diabetes** and research into the management of obesity. It is a **dual-acting agonist** that simultaneously targets **GLP-1 (glucagon-like peptide-1)** and **GIP (glucose-dependent insulinotropic polypeptide)** receptors, improving blood sugar control, weight management and metabolic health through multiple mechanisms.

### **Physical and chemical properties**

- **Chemical properties**:

- Tirzepatide is a **peptide drug** consisting of 39 amino acids, and its half-life is extended by chemical modification (fatty acid linking technology).

- Molecular formula: C225H348N48O68

- Molecular weight: approximately 4813.57 g/mol

- The structural design of Tirzepatide ensures that it activates both GLP-1 and GIP receptors, which enhances the metabolic effects of the drug.

- **Physical properties**:

- Appearance: Tirzepatide is usually a white to off-white lyophilized powder.

- Solubility: easily soluble in water, suitable for injection.

### **Mechanism of Action**

Tirzepatide mimics the effects of two incretin hormones (GLP-1 and GIP):

1. **GLP-1 receptor agonism**:

- Promotes insulin secretion and inhibits the release of glucagon.

- Delays gastric emptying and increases satiety.

- Improves pancreatic β-cell function.

2. **GIP receptor agonism**:

- Further enhances glucose-stimulated insulin secretion.

- Works synergistically with GLP-1 to improve insulin sensitivity and lipid metabolism.

This dual action makes Tirzepatide superior to traditional single GLP-1 agonists in lowering blood sugar and reducing weight.

### **Dosage and Use**

Tirzepatide is designed for **once-weekly subcutaneous injection**, suitable for the treatment of type 2 diabetes and is being studied for obesity management.

#### **Common Dosage Regimen**:

- **Starting dose**: 2.5 mg, once a week.

- **Step-up**: The dose is increased every 4 weeks, with common increasing doses of 5 mg, 7.5 mg, 10 mg or higher (up to 15 mg).

- **Maximum dose**: 15 mg/week.

Dose adjustment usually depends on the patient's tolerance and treatment goals (glycemic control, weight loss, etc.).

### **Half-life and pharmacokinetics**

- **Half-life**: About **5 days**, which makes it suitable for once-weekly injections.

- **Absorption**: Peak plasma concentration is reached 24-48 hours after subcutaneous injection.

- **Distribution**: The drug has a high binding rate to plasma proteins.

- **Metabolism**: Mainly degraded by peptidases and metabolized by the liver.

- **Excretion**: Metabolites are excreted through the kidneys and bile duct.

### **Treatment cycle**

- The treatment cycle depends on the patient's condition and treatment goals, and is usually long-term treatment.

- The goal for diabetic patients is to maintain blood sugar in the ideal range, and the goal of obesity management is to continue to lose weight.

### **Clinical effects**

1. **Glycemic control**:

- In patients with type 2 diabetes, Tirzepatide significantly reduced HbA1c (glycosylated hemoglobin), and many patients achieved normal blood sugar levels.

2. **Weight loss**:

- In studies, Tirzepatide performed well in promoting weight loss, especially in the high-dose group.

- Weight loss can reach **15%-22%** (dose-dependent).

3. **Metabolic improvement**:

- Improved insulin sensitivity.

- Reduced visceral fat.

### **Side effects**

Although Tirzepatide is generally well tolerated, common side effects include:

1. **Gastrointestinal reactions**:

- Nausea, vomiting, diarrhea, or constipation.

- Gastrointestinal discomfort is common at the beginning of dose increase, but usually gradually subsides.

2. **Hypoglycemia**:

- The risk of hypoglycemia is increased when used in combination with other glucose-lowering drugs (such as insulin or sulfonylureas).

3. **Other**:

- Decreased appetite (may be an expected effect).

- Fatigue, headache, or injection site reaction.

### **Contraindications and Precautions**

1. **Contraindications**:

- Hypersensitivity to Tirzepatide or its ingredients.

- Patients with a family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome (MEN 2).

2. **Precautions**:

- Patients with impaired liver and kidney function should use with caution.

- Safety and efficacy in minors have not been established.

- Pregnant or breastfeeding women should weigh the risks and benefits.

### **Market Position and Research Progress**

- **Marketing Status**: Tirzepatide was developed by **Eli Lilly** and was approved by the FDA in 2022 for the treatment of type 2 diabetes under the trade name **Mounjaro**.

- **Obesity Management Research**: In obese patients, Tirzepatide is considered to have significant weight loss potential and is in late-stage clinical trials.

### **Summary**

Tirzepatide is a dual incretin receptor agonist with significant potential in the management of diabetes and obesity. Its once-weekly dosing regimen, strong glycemic control and weight loss effects make it an important advance in the management of metabolic diseases. Although well tolerated, patients need to use it under the guidance of a physician to avoid side effects and potential risks.

Tirzepatide is a new type of glucose-lowering drug developed by Eli Lilly and Company in the United States with the trade name Mounjaro. It is the first dual-target glucagon-like peptide-1 (GLP-1) receptor agonist and glucagon receptor (GIP) agonist, which has been approved for the treatment of type 2 diabetes and has shown the potential for weight loss and metabolic improvement in clinical trials.

### **Applicable population**

1. **Main indication**:

- Used in conjunction with diet and exercise to improve blood sugar control in adult patients with type 2 diabetes.

2. **Possible expansion population**:

- Obese or overweight (not yet formally approved, only in the research stage).

- Suffering from obesity-related metabolic syndrome, such as hypertension, hyperlipidemia, etc.

- High-risk populations that are difficult to control weight through lifestyle interventions.

**Note**:

Tirzepatide is not suitable for:

- Patients with type 1 diabetes.

- Pregnant or lactating women.

- Patients with a history of pancreatitis.

### **How ​​it works**

Tirzepatide works by mimicking two natural incretin hormones (GLP-1 and GIP):

1. **GLP-1 (glucagon-like peptide-1) action**:

- Promotes insulin secretion from pancreatic β cells and lowers postprandial blood sugar.

- Slows down gastric emptying and prolongs satiety.

- Inhibits glucagon secretion and reduces liver glucose output.

2. **GIP (glucose-dependent insulin-releasing polypeptide) action**:

- Enhances pancreatic β cell function and promotes insulin secretion.

- Further improves blood sugar control based on the action of GLP-1.

- Promotes fat decomposition and oxidation, which helps weight management.

### **Usage and Dosage**

1. **Recommended starting dose**:

- Once a week, subcutaneous injection of 2.5 mg for drug adaptation.

2. **Gradual dose adjustment**:

- Increase the dose every 4 weeks to gradually reach the effective dose (5 mg, 7.5 mg, 10 mg, etc.).

3. **Maximum dose**:

- 15 mg per week.

**Precautions**:

- Each injection should be given at the same time on the same day.

- The abdomen, thigh or upper arm can be selected as the injection site.

- If a dose is missed, it should be made up as soon as possible within 72 hours, otherwise skip this time.

### **Common side effects**

1. **Gastrointestinal reactions**: nausea, vomiting, diarrhea, constipation.

2. **Hypoglycemia**: especially when used in combination with sulfonylureas or insulin.

3. **Other**: injection site reactions, dizziness, fatigue.

**Serious but rare side effects**:

- Pancreatitis.

- Risk of medullary thyroid cancer (need to exclude relevant medical history).

### **Clinical efficacy**

- Studies have shown that Tirzepatide is superior to traditional GLP-1 receptor agonists (such as Semaglutide) in controlling blood sugar.

- In terms of weight management, patients in the high-dose group lost an average of 15%-20% of their weight.

If you are considering using Tirzepatide, you should be evaluated by a professional doctor to determine if it is appropriate and to tailor your treatment plan to your individual circumstances.

Tirzepatide is an innovative drug developed by Eli Lilly and Company for the treatment of type 2 diabetes and related diseases, and has demonstrated significant results in obesity management. It is a dual receptor agonist that activates both the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulin secretory polypeptide (GIP) receptor. Here is a detailed look at the main benefits of Tirzepatide and its potential areas of application:

### 1. **Effectively control blood sugar levels**

- **Dual mechanism**: Tirzepatide reduces blood sugar more efficiently by simultaneously activating GLP-1 and GIP receptors, enhancing insulin secretion and inhibiting glucagon release.

- **Powerful Blood Glucose Control**: Studies show that compared with traditional GLP-1 receptor agonists, Tirzepatide performs better in reducing glycated hemoglobin (HbA1c) and can significantly reduce the long-term blood sugar burden in patients with type 2 diabetes. .

- **Lower risk of hypoglycemia**: Although it is a powerful drug, it has a low risk of causing hypoglycemia because its mechanism of action relies on blood sugar levels.

### 2. **Significant weight loss effect**

- **Powerful weight management effect**: Tirzepatide has shown excellent weight loss effects in clinical trials, with some patients losing more than 20% of their weight, approaching or exceeding the effects of bariatric surgery.

- **Dual target advantage**: Compared with drugs with a single mechanism of GLP-1, the synergistic effect of GIP makes Tirzepatide more effective in suppressing appetite, reducing energy intake and promoting lipolysis.

### 3. **Improve cardiovascular health**

- **REDUCED RISK OF CARDIOVASCULAR EVENTS**: Tirzepatide has protective effects on cardiovascular health by improving insulin sensitivity, lowering body weight and blood lipid levels, and reducing inflammation.

- **Reduces Blood Pressure and Cholesterol**: Studies have shown that it can significantly reduce patients' blood pressure levels and low-density lipoprotein (LDL) cholesterol, while increasing high-density lipoprotein (HDL) cholesterol.

### 4. **Improve metabolic syndrome**

- **Comprehensive Metabolic Regulation**: Tirzepatide helps improve multiple symptoms associated with metabolic syndrome, such as insulin resistance, dyslipidemia, and abdominal fat accumulation.

- **Promote the recovery of pancreatic islet function**: By reducing the burden on the pancreatic islets and improving the efficiency of insulin secretion, Tirzepatide may help delay the progression of type 2 diabetes.

### 5. **Potential Treatments for Non-Alcoholic Fatty Liver Disease (NAFLD)**

- **Improves liver fat accumulation**: In patients with obesity and type 2 diabetes, which is often associated with non-alcoholic fatty liver disease, Tirzepatide shows potential in treating NAFLD by reducing fat accumulation and lowering inflammation.

- **Reduce liver fibrosis**: Some studies suggest that Tirzepatide may be helpful in reducing liver fibrosis, which is important in reducing the risk of cirrhosis and liver cancer.

### 6. **Reduce the risk of multiple chronic diseases**

- **Multiple Health Benefits**: Through weight loss, improved blood sugar, and reduced inflammation, Tirzepatide helps reduce the risk of chronic diseases associated with obesity, such as high blood pressure, sleep apnea, and arthritis.

- **Long-term health improvement**: Tirzepatide's significant metabolic regulation effect makes it potentially suitable for use in a wider range of preventive health management areas.

### 7. **High patient compliance**

- **Convenient Dosing**: Tirzepatide is a once-weekly injection that is convenient for patients to use long-term.

- **Well Tolerated**: Although some patients may experience mild gastrointestinal side effects (such as nausea and diarrhea), most people tolerate the drug well.

### Future prospects

In addition to its significant advantages in the treatment of diabetes and obesity, Tirzepatide has received much attention for its potential in other areas, including:

- **Further Research in Cardiovascular Disease**: Explore the use of Tirzepatide in the prevention and treatment of atherosclerosis.

- **Oncometabolism**: Obesity is associated with certain cancers (such as breast cancer and liver cancer), and Tirzepatide may reduce the incidence of these cancers through weight management and metabolic improvements.

**Summarize**

Tirzepatide is a revolutionary drug that combines powerful blood sugar control and weight management capabilities while showing potential therapeutic effects on a variety of metabolic disorders and chronic diseases. As more clinical trials are conducted and long-term safety data accumulate, Tirzepatide may become the gold standard in the treatment of type 2 diabetes and obesity and play an important role in the broader field of metabolic diseases.

WhatsApp/Telegram:+852 6749 2648

Gmail:lucasraws207@gmail.com

Skype：live:.cid.8f21dc7fc6621ba7

Hot Tags: peptides tirzepatide 2/5/10mg cas：2023788-19-2, China peptides tirzepatide 2/5/10mg cas：2023788-19-2 manufacturers, suppliers, factory, GDF 8 Muscles are firmer and more defined, ACE 031 CAS 1621169 52 5, ACE 031 Add muscle mass and volume, MGF CAS 12020 86 9, AOD9604 CAS 221231 10 3, PT141 CAS 32780 32 8